secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-07-01T20:41:06+00:00
Accession:  0001193125-26-292704
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences licenses monospecific antibodies from Paragon for up to $22M in milestones
--------------------------------------------------------------------------------

- Paragon grants exclusive worldwide license to undisclosed target antibodies for all human therapeutic areas.
- Jade pays up to $22M in development/regulatory milestones; $1.5M already paid for candidate nomination.
- Additional sublicensing fees up to ~$20.1M on commercial milestones; royalties low to mid-single-digit.
- Paragon restricted from generating monospecific antibodies targeting same target for at least 5 years.
- Jade can terminate on 60 days' notice; agreement subject to standard termination provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526292704/0001193125-26-292704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526292704/d145208d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-292704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer